ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat

• Enveric stated that it intends to use the proceeds from the offering for product development, in addition to meeting its working capital and general corporate requirements.
• The company stated that the gross proceeds from the offering are expected to be about $5 million.
• Investors have an option to exercise Series I and short-term Series J warrants at a strike price of $2 per share, which would result in an additional fundraise of $8.9 million if fully exercised.

Shares of Enveric Biosciences Inc. (ENVB) are on track for their worst decline in more than 10 weeks after the company announced the pricing of a $13.9 million offering.

Enveric stated during after-market hours on Thursday that it has entered into definitive agreements to purchase and sell 2.2 million shares of its common stock at a purchase price of $2.25. This is at a discount of over 4% compared to Enveric’s closing price on Thursday.

Enveric shares were down nearly 13% in Friday’s pre-market trade, and if the trend holds into the regular session, this will be the ENVB stock’s worst decline since January this year.

How Did Retail Traders React?

Retail sentiment on Stocktwits around Enveric trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.

One user looked at the bright side of the private placement, noting that it helps the company secure funding for future growth.

Another user highlighted that Enveric’s offering has given the company enough money to survive.

Why Did Enveric Raise Funds?

Enveric stated that it intends to use the proceeds from the offering for product development, in addition to meeting its working capital and general corporate requirements.

The company stated that the gross proceeds from the offering are expected to be about $5 million. Additionally, investors may exercise Series I and short-term Series J warrants at a strike price of $2 per share, exercisable immediately upon issuance.

If these warrants are fully exercised on a cash basis, Enveric expects the gross proceeds to be approximately $8.9 million. The offering is expected to close on or about April 17, 2026.

Enveric announced last month that it had secured a new U.S. patent for its EVM301 series of drug candidates. This series includes EB-003, which is currently under development for the treatment of mental health disorders.

EB-003 is Enveric’s lead neuroplastogen, which the company says has the potential to address depression and anxiety without hallucinogenic effects. The company has so far secured 27 patents in the U.S. and currently has 60 pending applications across the U.S. and beyond.

ENVB stock is down 35% year-to-date and 84% over the past 12 months. The AdvisorShares Psychedelics ETF (PSIL) is up 72% over the past 12 months.

Also See: El-Erian Warns Economic Damage Due To Iran War Is Deepening — Says AI, Slow Death Of Washington Consensus Among Factors To Blame

For updates and corrections, email newsroom[at]stocktwits[dot]com.